Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-062080
Filing Date
2023-11-09
Accepted
2023-11-09 16:15:39
Documents
73
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q elvn-20230930.htm   iXBRL 10-Q 3080887
2 EX-31.1 elvn-ex31_1.htm EX-31.1 16330
3 EX-31.2 elvn-ex31_2.htm EX-31.2 16329
4 EX-32.1 elvn-ex32_1.htm EX-32.1 10016
5 EX-32.2 elvn-ex32_2.htm EX-32.2 10006
6 GRAPHIC img251749395_0.jpg GRAPHIC 28618
  Complete submission text file 0000950170-23-062080.txt   9778655

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT elvn-20230930_cal.xml EX-101.CAL 41889
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT elvn-20230930_pre.xml EX-101.PRE 353835
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT elvn-20230930_def.xml EX-101.DEF 212709
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT elvn-20230930.xsd EX-101.SCH 62856
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT elvn-20230930_lab.xml EX-101.LAB 478922
67 EXTRACTED XBRL INSTANCE DOCUMENT elvn-20230930_htm.xml XML 1538089
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39247 | Film No.: 231392654
SIC: 2834 Pharmaceutical Preparations